Sign in

CIK 0001880438

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

AN2 Therapeutics, Inc.

Sign in to watch
Ticker
ANTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
820606654
Phone
+1 650-331-9090
Business address
1300 EL CAMINO REAL, SUITE 100, MENLO PARK, CA, 94025
  1. 4 Derivatives Options or other derivatives
  2. 4 Derivatives Options or other derivatives
  3. 4 Derivatives Options or other derivatives
  4. 4 Derivatives Options or other derivatives
  5. 4 Derivatives Options or other derivatives
  6. 4 Derivatives Options or other derivatives
  7. 3 Insider Initial Statement of Ownership
  8. 4 Grant or award Director acquired 11,560 shares (grant or award)
  9. 4 Grant or award Director acquired 3,650 shares (grant or award)
  10. 4 Grant or award Director acquired 11,560 shares (grant or award)
  11. 4 Open-market sale Chief Financial Officer sold 8,807 shares at an average $1.01 ($8,883)
  12. 4 Open-market sale Chief Strategy Officer sold 6,462 shares at an average $1.01 ($6,507)
  13. 4 Open-market sale Chief Development Officer sold 9,251 shares at an average $1.01 ($9,332)
  14. 4 Open-market sale Eizen Joshua M sold 24,854 shares at an average $1.00 ($24,962)
  15. 4 Open-market sale Eizen Joshua M sold 2,819 shares at $1.14 ($3,214)
  16. 4 Open-market sale Chief Strategy Officer sold 765 shares at $1.14 ($872)
  17. 4 Grant or award Director acquired 10,367 shares (grant or award)
  18. 4 Grant or award Director acquired 10,367 shares (grant or award)
  19. 4 Grant or award Director acquired 3,274 shares (grant or award)
  20. 4 Grant or award Director acquired 11,875 shares (grant or award)

Page 3 of 11 · 216 filings